Regulators and institutions are grappling with widespread missing data across drug trials, federal programs, and business intelligence systems. The FDA is pressuring pharmaceutical developers to disclose incomplete trial data, while agencies like PEPFAR and the SBA face accountability issues from data gaps.
·FDA files concerns over missing data in Moderna's mRNA flu shot trial submissions
·FDA calls on drug developers to publish missing data from thousands of clinical trials
·SBA suspends 1,000 contractors for failing to meet data submission deadlines
·PEPFAR transparency hampered by missing data across health initiatives
·Organizations struggle to act on customer and research data without complete context
drawn from Pharmaceutical Executive, RTO Insider, The New York Times, Nature · updated 16d ago